When we remember events, we often do not only recall individual events, but also the connections between them. However, extant research has focused on how humans segment and remember discrete events from continuous input, with far less attention given to how the structure of connections between events impacts memory. Here we conduct a functional magnetic resonance imaging study in which participants watch and recall a series of realistic audiovisual narratives. By transforming narratives into networks of events, we demonstrate that more central events-those with stronger semantic or causal connections to other events-are better remembered. During encoding, central events evoke larger hippocampal event boundary responses associated with memory formation. During recall, high centrality is associated with stronger activation in cortical areas involved in episodic recollection, and more similar neural representations across individuals. Together, these results suggest that when humans encode and retrieve complex real-world experiences, the reliability and accessibility of memory representations is shaped by their location within a network of events.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307577 | PMC |
http://dx.doi.org/10.1038/s41467-022-31965-2 | DOI Listing |
Brain Cogn
January 2025
Key Laboratory of Brain, Cognition and Education Sciences, Ministry of Education, China. Electronic address:
Human experiences are inherently shaped by individual perspectives, leading to diverse interpretations of the same events. However, shared activities, such as communal film watching or sports viewing, underscore the dual nature of these experiences: collective joy arises through social interactions, while individual emotional responses are influenced by personal preferences. The neural mechanisms underlying this interplay between shared and idiosyncratic experiences, particularly in the context of reward processing, remain insufficiently explored.
View Article and Find Full Text PDFBr J Sociol
January 2025
Department of Sociology and Social Work, Aalborg University, Aalborg, Denmark.
This study contributes new insights into whether volunteering improves the employment prospects of jobless individuals by examining its relationship with the speed at which they secure new jobs- an outcome that has received limited attention in previous research. Our comprehensive data enables us to investigate this by constructing an event history dataset that merges information from the Danish Volunteer Survey with administrative register data. Our results show that when we adjust for variations in education and labor market experience, jobless individuals who volunteer remain unemployed approximately two weeks or 31 percent longer than those who do not.
View Article and Find Full Text PDFLeuk Lymphoma
January 2025
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
This retrospective study aimed to evaluate the efficacy and safety of PBVD (pegylated liposomal doxorubicin [PLD], bleomycin, vinblastine, and dacarbazine) in the first-line treatment of classical Hodgkin lymphoma (cHL) patients with cardiovascular risk factors. Overall, 84 patients (53 had stage I-II and 31 had stage III-IV disease) received PBVD. The median PLD treatment duration was 16 weeks (interquartile range [IQR]: 8-24) for stage I-II and 24 weeks (IQR: 12-24) for stage III-IV.
View Article and Find Full Text PDFAm J Sports Med
January 2025
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Background: Selective androgen receptor modulators (SARMs) are small-molecule compounds that exert agonist and antagonist effects on androgen receptors in a tissue-specific fashion. Because of their performance-enhancing implications, SARMs are increasingly abused by athletes. To date, SARMs have no Food and Drug Administration approved use, and recent case reports associate the use of SARMs with deleterious effects such as drug-induced liver injury, myocarditis, and tendon rupture.
View Article and Find Full Text PDFRheumatol Ther
January 2025
Biosplice Therapeutics, Inc., 9360 Towne Centre Dr, San Diego, CA, 92121, USA.
Introduction: Lorecivivint (LOR), a CDC-like kinase/dual-specificity tyrosine kinase (CLK/DYRK) inhibitor thought to modulate inflammatory and Wnt pathways, is being developed as a potential intra-articular knee osteoarthritis (OA) treatment. The objective of this trial was to evaluate long-term safety of LOR within an observational extension of two phase 2 trials.
Methods: This 60-month, observational extension study (NCT02951026) of a 12-month phase 2a trial (NCT02536833) and 6-month phase 2b trial (NCT03122860) was administratively closed after 36 months as data inferences became limited.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!